Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer

NEXT STORY
OpGen and Curetis Successfully Close their Business Combination Transaction
PREV STORY
The Steadman Clinic Uses Modernizing Medicine’s Telehealth Solution to Treat Patients During COVID-19 Pandemic
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Bavarian Nordic Introduces New Incentive Programs for Executive Management and Employees

COPENHAGEN, Denmark, December 8, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced ...

author_avatar
NASDAQ Market News

APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer

author_avatar
NASDAQ Market News

NuFACTOR Specialty Pharmacy is Welcoming Applications for the 2019 Annual Eric Dostie Memorial College Scholarship

author_avatar
NASDAQ Market News